
Please try another search
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Name | Age | Since | Title |
---|---|---|---|
Kenneth R. Chapman | - | 2024 | Member of INBRX-101 Scientific Advisory Board |
John Faiz Kayyem | 60 | 2024 | Independent Director |
Kimberly J. Manhard | 64 | 2024 | Independent Director |
Igor Barjaktarevic | - | 2024 | Member of INBRX-101 Scientific Advisory Board |
Robert A. Sandhaus | - | 2024 | Member of INBRX-101 Scientific Advisory Board |
Mark Brantly | - | 2024 | Member of INBRX-101 Scientific Advisory Board |
Noel Gerry McElvaney | - | 2024 | Member of INBRX-101 Scientific Advisory Board |
Douglas Gorman Forsyth | 55 | 2024 | Independent Director |
James K. Stoller | - | 2024 | Member of INBRX-101 Scientific Advisory Board |
Kristiina Vuori | 56 | 2024 | Independent Director |
Mark Paul Lappe | 57 | 2024 | Founder, CEO & Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review